These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 22437443)

  • 1. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
    Visco C; Li Y; Xu-Monette ZY; Miranda RN; Green TM; Li Y; Tzankov A; Wen W; Liu WM; Kahl BS; d'Amore ES; Montes-Moreno S; Dybkær K; Chiu A; Tam W; Orazi A; Zu Y; Bhagat G; Winter JN; Wang HY; O'Neill S; Dunphy CH; Hsi ED; Zhao XF; Go RS; Choi WW; Zhou F; Czader M; Tong J; Zhao X; van Krieken JH; Huang Q; Ai W; Etzell J; Ponzoni M; Ferreri AJ; Piris MA; Møller MB; Bueso-Ramos CE; Medeiros LJ; Wu L; Young KH
    Leukemia; 2012 Sep; 26(9):2103-13. PubMed ID: 22437443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
    Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
    Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
    Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Evens AM; Sehn LH; Farinha P; Nelson BP; Raji A; Lu Y; Brakman A; Parimi V; Winter JN; Schumacker PT; Gascoyne RD; Gordon LI
    J Clin Oncol; 2010 Feb; 28(6):1017-24. PubMed ID: 20048181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
    Zhao S; Dong X; Shen W; Ye Z; Xiang R
    Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
    Ott G; Ziepert M; Klapper W; Horn H; Szczepanowski M; Bernd HW; Thorns C; Feller AC; Lenze D; Hummel M; Stein H; Müller-Hermelink HK; Frank M; Hansmann ML; Barth TF; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Loeffler M; Rosenwald A
    Blood; 2010 Dec; 116(23):4916-25. PubMed ID: 20736456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Gutiérrez-García G; Cardesa-Salzmann T; Climent F; González-Barca E; Mercadal S; Mate JL; Sancho JM; Arenillas L; Serrano S; Escoda L; Martínez S; Valera A; Martínez A; Jares P; Pinyol M; García-Herrera A; Martínez-Trillos A; Giné E; Villamor N; Campo E; Colomo L; López-Guillermo A;
    Blood; 2011 May; 117(18):4836-43. PubMed ID: 21441466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW; Steidl C; Sehn LH; Gascoyne RD
    Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.
    Huang X; Meng B; Iqbal J; Ding BB; Perry AM; Cao W; Smith LM; Bi C; Jiang C; Greiner TC; Weisenburger DD; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Gascoyne RD; Cook JR; Tubbs RR; Jaffe ES; Armitage JO; Vose JM; Staudt LM; McKeithan TW; Chan WC; Ye BH; Fu K
    J Clin Oncol; 2013 Dec; 31(36):4520-8. PubMed ID: 24220563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
    Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
    Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
    Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
    Shustik J; Han G; Farinha P; Johnson NA; Ben Neriah S; Connors JM; Sehn LH; Horsman DE; Gascoyne RD; Steidl C
    Haematologica; 2010 Jan; 95(1):96-101. PubMed ID: 19797725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
    Rimsza LM; Leblanc ML; Unger JM; Miller TP; Grogan TM; Persky DO; Martel RR; Sabalos CM; Seligmann B; Braziel RM; Campo E; Rosenwald A; Connors JM; Sehn LH; Johnson N; Gascoyne RD
    Blood; 2008 Oct; 112(8):3425-33. PubMed ID: 18544678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
    Salles G; de Jong D; Xie W; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Calaminici M; Sander B; Thorns C; Campo E; Molina T; Lee A; Pfreundschuh M; Horning S; Lister A; Sehn LH; Raemaekers J; Hagenbeek A; Gascoyne RD; Weller E
    Blood; 2011 Jun; 117(26):7070-8. PubMed ID: 21536860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.
    Gu K; Weisenburger DD; Fu K; Chan WC; Greiner TC; Aoun P; Smith LM; Bast M; Liu Z; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Hematol Oncol; 2012 Sep; 30(3):143-9. PubMed ID: 22009820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.